Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
Protara Therapeutics, Inc. filed a prospectus supplement updating its existing resale registration covering up to 21,686,760 shares of common stock. These shares include currently held common stock as well as shares issuable upon exercise of pre-funded warrants and common warrants held by selling stockholders.
The update adds Funicular Funds, LP as a selling stockholder following an assignment on January 28, 2026 by OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 common stock warrant shares. Funicular Funds, LP does not own common stock as of January 30, 2026 and is subject to a 4.99% beneficial ownership limitation after warrant exercises.
Protara Therapeutics VP, Controller Hannah Fry reported a tax-related share withholding. On 01/26/2026, 1,457 shares of Protara Therapeutics common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 24, 2025. After this withholding, Fry beneficially owned 42,723 shares of Protara common stock in direct ownership.
Protara Therapeutics, Inc. Chief Financial Officer Patrick Fabbio reported an automatic share withholding related to equity compensation. On 01/26/2026, 3,261 shares of common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations arising from the vesting of a previously granted restricted stock unit award. After this tax withholding, Fabbio directly beneficially owns 64,115 shares of Protara common stock.
Protara Therapeutics CEO and President Jesse Shefferman, a director of Protara Therapeutics, Inc. (TARA), reported a routine share withholding related to equity compensation. On January 26, 2026, the company withheld 8,732 shares of common stock at $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award granted on January 24, 2025. After this tax withholding, Shefferman beneficially owns 1,021,832 shares of Protara common stock directly.
Protara Therapeutics reported an insider share withholding by its Chief Scientific Operations Officer, Jacqueline Zummo. On January 26, 2026, 3,724 shares of common stock were withheld at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award that was granted on January 24, 2025. After this tax-related transaction, Zummo beneficially owns 118,559 shares of Protara common stock directly.
Protara Therapeutics, Inc. CEO and President Jesse Shefferman reported a Form 4 transaction involving company common stock. On January 20, 2026, 16,322 shares of Protara Therapeutics common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations tied to previously granted restricted stock unit awards that vested. After this tax withholding, Shefferman beneficially owned 1,030,564 shares of Protara common stock directly.
Protara Therapeutics Chief Financial Officer reports tax-related share withholding. On January 20, 2026, CFO Patrick Fabbio had 3,063 shares of common stock withheld by Protara Therapeutics to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 19, 2024. The shares were treated as a disposition at $5.60 per share, and Fabbio now directly holds 67,376 shares of Protara Therapeutics common stock after this administrative transaction.
Protara Therapeutics, Inc. officer Jacqueline Zummo reported a tax-related share withholding transaction. On January 20, 2026, 6,578 shares of Protara common stock were withheld by the company at a price of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards granted to her in January 2023 and January 2024.
After this withholding, Zummo directly beneficially owned 122,283 shares of Protara common stock. The filing characterizes the event as an automatic share withholding for taxes rather than an open-market sale.
Protara Therapeutics VP and Controller Hannah Fry reported a routine share withholding related to equity compensation. On January 20, 2026, the company withheld 2,132 shares of common stock at a value of $5.60 per share to cover income tax obligations arising from the vesting of restricted stock unit awards originally granted on January 19, 2023 and January 19, 2024. After this tax-related transaction, Fry beneficially owned 44,180 shares of Protara Therapeutics common stock in direct ownership.
Protara Therapeutics reported new equity awards for its Chief Commercial Officer, William Conkling. On January 16, 2026, he received 26,000 shares of common stock at no cost, issued as restricted stock units. These RSUs vest in three equal installments on the first, second, and third anniversaries of January 16, 2026, as long as he remains with the company.
He was also granted stock options covering 158,000 shares of common stock at an exercise price of $5.01 per share, expiring on January 15, 2036. For these options, 25% of the shares vest on the one-year anniversary of January 16, 2026, and the remaining 75% vest in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 76,000 common shares and 158,000 options.